Related articles

Lung cancer remains one of the most challenging malignancies worldwide due to its high mortality rate and often late-stage diagnosis. Early detection and personalized care strategies are critical in improving patient outcomes. RGCC’s Circulating Tumor Cell (CTC) testing offers a promising approach for monitoring lung cancer progression, treatment response, and recurrence risk. This article explores the latest clinical applications of RGCC CTC testing in lung cancer care.

When doctors diagnose cancer, they classify it into different stages to determine the tumor’s size, spread, and severity. Cancer staging not only helps in deciding the best treatment plan but also in predicting survival rates. Below is a detailed explanation of cancer stages from Stage 0 to Stage 4 in a simple and easy-to-understand way.

After completing cancer care, patients enter the recovery period, but this phase is not foolproof. Although care has ended, the risk of cancer recurrence still exists. Therefore, managing and continuously monitoring the recovery period is crucial. The frequency of monitoring will vary depending on the patient’s specific situation, cancer type, and individual health condition. Through regular monitoring, the medical team can detect potential signs of recurrence early and adjust care plans promptly to reduce the risk of recurrence and promote long-term recovery.

In cancer care, adjusting care plans becomes crucial as a patient’s condition changes. With the advancement of modern care testing technologies, the care team can monitor the patient’s health status and response to care in real-time, adjusting the care plan promptly based on the testing data to achieve optimal outcomes. These testing data not only provide specific information regarding tumor progression but also help the care team understand the patient’s immune status, metabolic features, and other key indicators, thus enabling precise and personalized care.

In cancer care, developing a personalized care plan for each patient is crucial, especially during the initial diagnosis phase. This phase is not only the starting point for medical record collection and diagnosis but also a critical moment for determining the direction of future care. Scientific testing methods can help medical teams fully understand a patient’s health status, cancer risks, metabolic characteristics, and more, thereby establishing a personalized care baseline. These tests provide real-time data that serve as an important reference for future care adjustments.